Regeneron Pharmaceuticals' Cost of Revenue rose 7.13% to $281.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 12.74%. This contributed to the annual value of $1.1 billion for FY2024, which is 16.65% up from last year.
According to the latest figures from Q3 2025, Regeneron Pharmaceuticals' Cost of Revenue is $281.0 million, which was up 1.96% from $275.6 million recorded in Q2 2025.
In the past 5 years, Regeneron Pharmaceuticals' Cost of Revenue ranged from a high of $811.7 million in Q4 2021 and a low of $149.2 million during Q2 2022.
Its 3-year average for Cost of Revenue is $259.5 million, with a median of $258.6 million in 2023.
Its Cost of Revenue has fluctuated over the past 5 years, first spiked by 367.84% in 2021, then plummeted by 72.34% in 2022.
Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Cost of Revenue stood at $811.7 million in 2021, then tumbled by 65.75% to $278.0 million in 2022, then decreased by 6.98% to $258.6 million in 2023, then grew by 26.37% to $326.8 million in 2024, then grew by 7.13% to $281.0 million in 2025.
Its last three reported values are $281.0 million in Q3 2025, $275.6 million for Q2 2025, and $265.5 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value